SHANGHAI
With the development of clinical translation, the immunotherapy industry, especially the cellular immunotherapy, is gaining popularity as an emerging biotherapy method. On April 10-11, 2015, the Immunotherapy Industry Summit 2015 — Cellular Immunotherapy Focus organized by CBI Pharma, a subsidiary of ENMORE, will be held in Guangzhou, China.
The summit will discuss hot topics of cellular immunotherapy covering the whole industry, offering a high-level platform to the insiders. More than 200 attendees from hospitals, research institutes, companies and equipment suppliers are expected. The summit will gather leading academic and clinical experts all over the world to share insights on market forecast, key technique development and application of clinical translation.
[Keynote Speeches]
Opportunities and Challenges
- Analysis of Government Opinions on Cellular Immunotherapy
- Analysis of New Technology of Immunotherapy and Marketing Segments
- How to Create Innovative Cooperation and Accelerate Development of Cellular Immunotherapy Industry
- Opportunities and Challenges: Investment Focus of Cellular Immunology Industry
Clinical Usage of Adoptive Cellular Immunotherapy Technology
- DC-CIK Cell Targeting Enhancement and Its Clinical Data Analysis
- Extensive In Vitro Autologous Cell Culture and Its Quality Control
- NK Cell In-vitro-amplification and Its Activation by Antigen Inducement
- Clinical Effect Evaluation of Adoptive Cellular Therapy and Prediction of Its Clinical Application
- How to Accelerate Translational Research in Cellular Immunotherapy Sphere: From the Basic to the Clinical
Research of Novel Immunotherapy
- Proposing and Discovering: Antigen of Tumor-targeted Therapy
- Anti-PD-L1/PD-1 and Tumor Immunotherapy
- TCR Transgenic T Cell and Research of Tumor Immunology
- Application of CAR T Cell in Tumor Immunotherapy
- Evaluation and Control: Clinical Side-effects of Immunotherapy
- Clinical Application of Cellular Immunotherapy and Antibody Drugs Combination Therapy
- Individual Therapy of Cancer: How to Choose the Most Effective Immunotherapy
- Future Development for Combination of Cellular Immunotherapy and Antibody Drugs
[Keynote Speakers]
- Dr. Jianchuan XIA, Professor and Director of Cell Therapy and Healthcare Research Center, Sun Yat-sen University Cancer Center
- Dr. Qijun QIAN, Director of Tumor Biotherapy Department, EHBH
- Dr. Lin YANG, Distinguished Professor, HEMATOLOGY CENTER, CYRUS TANG MEDICAL INSTITUTE, SOOCHOW UNIVERSITY
[Supporters]
- Guangzhou Medical University
- State Key Laboratory of Respiratory Disease
- Guangzhou Pubang Bio-immunological Tech Research Institute
CONTACT
ENMORE
Abby ZENG, +86-21-51551610
Fax: +86-21-51552421
abbyzeng@enmore.com
